Klinik und Poliklinik für Neurologie

Publikationen 2009

Bähr O, Herrlinger U, Weller M, Steinbach JP. Very late relapses in glioblastoma long-term survivors. J Neurol. 2009;256(10):1756-8.

Bernard V, Minnerop M, Bürk K, Kreuz F, Gillessen-Kaesbach G, Zühlke C. Exon deletions and intragenic insertions are not rare in ataxia with oculomotor apraxia 2. BMC Med Genet. 2009;10:87.

Bode FJ, Stephan M, Wiehager S, Nguyen HP, Björkqvist M, von Hörsten S, Bauer A, Petersén A. Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model. Behav Brain Res. 2009;205(1):175-82.

Boes M, Bauer J, Urbach H, Elger CE, Frank S, Baron M, Zsurka G, Kunz WS, Kornblum C. Proof of progression over time: finally fulminant brain, muscle, and liver affection in Alpers syndrome associated with the A467T POLG1 mutation. Seizure. 2009;18(3):232-4.

Boy J, Schmidt T, Wolburg H, Mack A, Nuber S, Böttcher M, Schmitt I, Holzmann C, Zimmermann F, Servadio A, Riess O. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum Mol Genet. 2009;18(22):4282-95.

Bürk K, Mälzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hübsch T, Hering S, Lindig TM, Haug V, Timmann D, Degen I, Kruse B, Dörr JM, Ratzka S, Ivo A, Schöls L, Boesch S, Klockgether T, Klopstock T, Schulz JB. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord. 2009;24(12):1779-84.

Clement AB, Gamerdinger M, Tamboli IY, Lütjohann D, Walter J, Greeve I, Gimpl G, Behl C. Adaptation of neuronal cells to chronic oxidative stress is associated with altered cholesterol and sphingolipid homeostasis and lysosomal function. J Neurochem. 2009;111(3):669-82.

De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D, Heubach JF, Sandbrink R, Tyblova M, Lelkova P, Steering committee of the BENEFIT study , Steering committee of the BEYOND study , Steering committee of the LTF study , Steering committee of the CCR1 study , Havrdova E, Pohl C, Horakova D, Ascherio A, Hafler DA, Karlson EW. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol. 2009;8(12):1111-9.

Fuchs J, Mueller JC, Lichtner P, Schulte C, Munz M, Berg D, Wüllner U, Illig T, Sharma M, Gasser T. The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol Aging. 2009;30(5):731-8.

Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol. 2009;27(8):1257-61.

Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U. Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. Oncology. 2009;76(3):184-9.

Heneka MT. Noradrenergic denervation facilitates the release of acetylcholine and serotonin in the hippocampus: towards a mechanism underlying upregulations described in MCI patients. Exp Neurol. 2009;217(2):237-9.

Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F. Should Intra-cerebrospinal Fluid Prophylaxis Be Part of Initial Therapy for Patients With Non-Hodgkin Lymphoma: What We Know, and How We Can Find Out More. Semin Oncol. 2009;36 Suppl. (4):S25-S34.

Himmelbach M, Erb M, Klockgether T, Moskau S, Karnath HO. fMRI of global visual perception in simultanagnosia. Neuropsychologia. 2009;47(4):1173-7.

Jäger S, Leuchtenberger S, Martin A, Czirr E, Wesselowski J, Dieckmann M, Waldron E, Korth C, Koo EH, Heneka M, Weggen S, Pietrzik CU. alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation. J Neurochem. 2009;111(6):1369-82.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C, BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987-97.

Kesper K, Kornblum C, Reimann J, Lutterbey G, Schröder R, Wattjes MP. Pattern of skeletal muscle involvement in primary dysferlinopathies: a whole-body 3.0-T magnetic resonance imaging study. Acta Neurol Scand. 2009;120(2):111-8.

Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, Alferink J, Alferink J, Nowak N, Novak N, Beyer M, Mayer G, Langhans B, Klockgether T, Waisman A, Eberl G, Schultze J, Famulok M, Kolanus W, Glass C, Kurts C, Knolle PA. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med. 2009;206(10):2079-89.

Klotz L, Hucke S, Thimm D, Classen S, Gaarz A, Schultze J, Edenhofer F, Kurts C, Klockgether T, Limmer A, Knolle P, Burgdorf S. Increased antigen cross-presentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1. J Immunol. 2009;183(1):129-36.

Klotz L, Schmidt S, Heun R, Klockgether T, Kölsch H. Association of the PPARgamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis. Neurosci Lett. 2009;449(1):81-3.

Kummer MP, Maruyama H, Huelsmann C, Baches S, Weggen S, Koo EH. Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase. J Biol Chem. 2009;284(4):2296-306.

Linnebank M, Moskau S, Jürgens A, Simon M, Semmler A, Orlopp K, Glasmacher A, Bangard C, Vogt-Schaden M, Urbach H, Schmidt-Wolf IG, Pels H, Schlegel U. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro-oncol. 2009;11(1):2-8.

Minnerop M, Specht K, Ruhlmann J, Grothe C, Wüllner U, Klockgether T. In vivo voxel-based relaxometry in amyotrophic lateral sclerosis. J Neurol. 2009;256(1):28-34.

Moraal B, Meier DS, Poppe PA, Geurts JJ, Vrenken H, Jonker WM, Knol DL, van Schijndel RA, Pouwels PJ, Pohl C, Bauer L, Sandbrink R, Guttmann CR, Barkhof F. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology. 2009;250(2):506-14.

Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol. 2009;66(11):1345-52.

Moskau S, Semmler A, Stoffel-Wagner B, Linnebank M. Plasma homocysteine levels after acute stroke and in the convalescent phase. Can J Neurol Sci. 2009;36(6):789-90.

Mueller MC, Jüptner U, Wuellner U, Wirz S, Türler A, Hirner A, Standop J. Parkinson's disease influences the perioperative risk profile in surgery. Langenbecks Arch Surg. 2009;394(3):511-5.

Mueller T, Breuer P, Schmitt I, Walter J, Evert BO, Wüllner U. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum Mol Genet. 2009;18(17):3334-43.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, BEYOND Study Group , O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Harung HP, Kappos L, Jeffery D, Comi G. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-97.

Papi A, Tatenhorst L, Terwel D, Hermes M, Kummer MP, Orlandi M, Heneka MT. PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem. 2009;109(6):1779-90.

Paus S, Gadow F, Knapp M, Klein C, Klockgether T, Wüllner U. Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Mov Disord. 2009;24(7):1080-4.

Popp J, Schaper K, Kölsch H, Cvetanovska G, Rommel F, Klingmüller D, Dodel R, Wüllner U, Jessen F. CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2009;30(3):498-500.

Rakovic A, Stiller B, Djarmati A, Flaquer A, Freudenberg J, Toliat MR, Linnebank M, Kostic V, Lohmann K, Paus S, Nürnberg P, Kubisch C, Klein C, Wüllner U, Ramirez A. Genetic association study of the P-type ATPase ATP13A2 in late-onset Parkinson's disease. Mov Disord. 2009;24(3):429-33.

Reimann J, Jacobson L, Vincent A, Kornblum C. Endplate destruction due to maternal antibodies in arthrogryposis multiplex congenita. Neurology. 2009;73(21):1806-8.

Schmitt I, Bitoun E, Manto M. PTPRR, cerebellum, and motor coordination. Cerebellum. 2009;8(2):71-3.

Schmitz-Hübsch T, Schlaepfer TE, Westheide J, von Falkenhausen M, Cooper-Mahkorn D, Maier W, Kühn KU. Clozapine: acquittal of the usual suspect. World J Biol Psychiatry. 2009;10(4 Pt 3):981-4.

Schneider CB, Ziemssen T, Schuster B, Seo HS, Haehner A, Hummel T. Pupillary responses to intranasal trigeminal and olfactory stimulation. J Neural Transm. 2009;116(7):885-9.

Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wüllner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol. 2009;65(5):610-4.

Schrag A, Spottke A, Quinn NP, Dodel R. Comparative responsiveness of Parkinson's disease scales to change over time. Mov Disord. 2009;24(6):813-8.

Velázquez-Pérez L, Seifried C, Abele M, Wirjatijasa F, Rodríguez-Labrada R, Santos-Falcón N, Sánchez-Cruz G, Almaguer-Mederos L, Tejeda R, Canales-Ochoa N, Fetter M, Ziemann U, Klockgether T, Medrano-Montero J, Rodríguez-Díaz J, Laffita-Mesa JM, Auburger G. Saccade velocity is reduced in presymptomatic spinocerebellar ataxia type 2. Clin Neurophysiol. 2009;120(3):632-5.

von Kleist-Retzow JC, Kornblum C. Mitochondrial disorders. Med. Genet. 2009;21(3):358-66.

Waschbüsch D, Born S, Niediek V, Kirchgessner N, Tamboli IY, Walter J, Merkel R, Hoffmann B. Presenilin 1 affects focal adhesion site formation and cell force generation via c-Src transcriptional and posttranslational regulation. J Biol Chem. 2009;284(15):10138-49.

Weberpals M, Hermes M, Hermann S, Kummer MP, Terwel D, Semmler A, Berger M, Schäfers M, Heneka MT. NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits. J Neurosci. 2009;29(45):14177-84.

Wischke C, Zimmermann J, Wessinger B, Schendler A, Borchert HH, Peters JH, Nesselhut T, Lorenzen DR. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int J Pharm. 2009;365(1-2):61-8.

Wüllner U, Schmitt I, Kammal M, Kretzschmar HA, Neumann M. Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry. 2009;80(4):449-50.

Xavier CP, Rastetter RH, Stumpf M, Rosentreter A, Müller R, Reimann J, Cornfine S, Linder S, van Vliet V, Hofmann A, Morgan RO, Fernandez MP, Schröder R, Noegel AA, Clemen CS. Structural and functional diversity of novel coronin 1C (CRN2) isoforms in muscle. J Mol Biol. 2009;393(2):287-99.